Skip to main content

UCB Medicines: Clinical Studies and Scientific Research Publication

Publications

Filter
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:

*Includes seizure clusters and acute or prolonged seizures

146 result(s)

phase 3

ZILBRYSQ® (zilucoplan)

Generalized Myasthenia Gravis
View

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

James F Howard Jr, Bresch Saskia, Genge Angela et al.  May 01, 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab, or secukinumab: Results from phase III/IIIb trials.

Kokolakis Georgios, Warren B. Richard, Strober Bruce et al.  February 22, 2023
phase 2

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE 

Philip J Mease, Akihiko Asahina, Gladman D. Dafna et al.  February 01, 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Desiree van der Heijde, Deodhar A. Atul, Xenofon Baraliakos et al.  January 17, 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

Iain B McInnes, Akihiko Asahina, Laura C Coates et al.  January 07, 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Joseph F. Merola, Landewé B.M. Robert, Iain B McInnes et al.  January 07, 2023
phase 2

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

Xenofon Baraliakos, Deodhar Atul, Dougados Maxime et al.  November 22, 2022
phase 3

NAYZILAM® (midazolam) CIV

Seizure Emergencies
View

Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: results of a phase 3, open-label extension trial

Tze-Chiang Meng, Jerzy P Szaflarski, Linda Chen et al.  November 18, 2022
phase 2

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study 

Laura C Coates, Iain B McInnes, Joseph F Merola et al.  November 18, 2022
phase 3

FINTEPLA® (fenfluramine)

Lennox-Gastaut Syndrome
View

Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study

Kelly G Knupp, Ingrid E Scheffer, Berten Ceulemans et al.  November 09, 2022